Astellas Pharma is interested in using tamper-evident, patient-controlled records to condition payment on the outcome a patient achieves rather than the population average reported in clinical trials.
Public source
Publisher name
Public post
Where are we really with blockchain in pharma, and where is it actually going? Not where the 2017 hype promised. There is no wholesale rebuild of patient records on a pu…
Company
Astellas Pharma
Astellas is committed to turning innovative science into VALUE for patients.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
About Astellas Pharma
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines
See moreLatest activity
Latest activity from Astellas Pharma
12 signals
Presence & Recognition
Astellas Pharma is participating in the 6th iPSC Drug Development Summit this week to explore opportunities and challenges shaping the future of cell therapies derived from induced pluripotent stem cells.
Presence & Recognition
Astellas Pharma announced that Astellas, BioLabs Global (U.S.), iCONM in collaboration with BioLabs, and LINK-J will co-host the Investor Day Japan Fall 2026 pitch event on November 11.
People
Astellas Pharma completed the Astellas AI Academy to explore how AI supports scientific content creation while maintaining compliance, quality, and scientific rigor.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Takeda
Takeda published a paper capturing a shift in patient behavior where patients are already using generative AI to navigate complex disease journeys.
Research & Knowledge
PharmaLedger Association
PharmaLedger Association published the final part of its four-part series examining why progress remains slow and setting out a practical acceleration agenda.
Research & Knowledge
Ethicos Health
Ethicos Health believes it's time to look differently at high cost medications by paying only for those that work commensurate with their performance.
Research & Knowledge
Ledger Run
Ledger Run CTO Patrick Mizer published an article in Applied Clinical Trials discussing why the infrastructure behind site payments is overdue for a redesign and how payment reliability impacts sponsor-site relationships.
Research & Knowledge
AstraZeneca